Incyte Corp. will establish the new headquarters of Incyte Europe S.a.r.l in Geneva, Switzerland and expects to occupy the 9,000 sq. ft. facility by mid-2015. Incyte Europe will serve as the base for the conduct of its European clinical development operations.

“The establishment of Incyte Europe in Geneva is a natural step in our company’s evolution,” said Hervé Hoppenot, president and chief executive officer of Incyte Corp. “Incyte has a broad and growing pipeline of proprietary, wholly-owned products, and we expect that this new facility in the center of Europe will enable us to create the infrastructure needed to support our global drug development programs, and to bring additional, potentially life-changing medicines to patients with cancer.”